Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its investigational product, KYS202003A. The Chinese company is set to initiate a clinical study assessing this Category 1 biologic product for the treatment of advanced solid tumors.
KYS202003A: A Self-Developed Oncolytic Virus Product
KYS202003A is a self-developed oncolytic virus product that expresses human interleukin-2 (hIL-2) using the Newcastle disease virus as a vector. This innovative product is designed for the treatment of advanced solid tumors and works through a multifaceted mechanism of action. It selectively infects tumor cells, inducing the formation of syncytia, which directly lyses tumor cells and releases tumor-specific antigens. This process activates T cells and NK cells, triggering anti-tumor immune responses and synergistically enhancing anti-tumor activity.
Initiating Clinical Studies for Advanced Solid Tumors
The receipt of clinical clearance from the NMPA marks a significant step forward for Jiangsu Kanion Pharmaceutical as it prepares to investigate the safety and efficacy of KYS202003A in clinical studies. The potential of this oncolytic virus product to revolutionize cancer treatment is significant, offering a novel approach to targeting and destroying tumor cells while stimulating the body’s immune response against cancer.-Fineline Info & Tech
